Article Text

Download PDFPDF

Omega-3 polyunsaturated fatty acid intake norms and preterm birth rate: a cross-sectional analysis of 184 countries
  1. Timothy H Ciesielski1,2,3,
  2. Jacquelaine Bartlett1,3,
  3. Scott M Williams1,3
  1. 1Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA
  2. 2Ronin Institute, Montclair, New Jersey, USA
  3. 3The Institute for Quantitative Biomedical Sciences, Dartmouth College, Hanover, New Hampshire, USA
  1. Correspondence to Dr Timothy H Ciesielski; timothyhciesielski{at}


Background The preponderance of evidence now indicates that elevated long-chain omega-3 polyunsaturated fatty acid (LC omega-3 PUFA) intake is often associated with reduced risk of preterm birth (PTB). This conclusion is based on recent meta-analyses that include several studies that reported null findings. We probed the reasons for this heterogeneity across studies and its implications for PTB prevention using country-level data.

Methods We analysed the relationship between national PTB rates (<37 weeks of gestation) and omega-3 PUFA intake norms from 184 countries for the year 2010. To estimate the total LC omega-3 PUFA levels (eicosapentaenoic acid [EPA]/docosahexaenoic acid [DHA]) that these norms produce we utilised a metric that accounts for (1) seafood-based omega-3 intake (EPA/DHA) and (2) plant-based omega-3 intake (alpha-linolenic acid [ALA]), ~20% of which is converted to EPA/DHA in vivo. We then assessed the shape of the omega-3–PTB relationship with a penalised spline and conducted linear regression analyses within the linear sections of the relationship.

Results Penalised spline analyses indicated that PTB rates decrease linearly with increasing omega-3 levels up to ~600 mg/day. Income-adjusted linear regression analysis among the countries in this exposure range indicated that the number of PTBs per 100 live births decreases by 1.5 (95% CI 2.8 to 0.3) for each 1 SD increase in omega-3 intake norms (383 mg/day).

Conclusions Taken with prior evidence for a causal association on the individual level, our findings indicate that omega-3 PUFA deficiency may be a widespread contributing factor in PTB risk. Consideration of baseline omega-3 PUFA levels is critical in the design of future interventions.

  • diet
  • omega-3
  • poly-unsaturated-fatty-acid
  • preterm birth
  • prevention
  • food systems

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from

Strengths and limitations of this study

  • This study helps to explain why it took over 33 years to confirm that elevated long-chain omega-3 polyunsaturated fatty acid (LC omega-3 PUFA) intakes are associated with reduced risk of preterm birth (PTB).

  • Our analysis of country-level omega-3 intake norms and PTB rates illuminates three critical factors that were only sporadically addressed in the prior studies: (1) baseline intake rates, (2) alternative dietary sources of LC omega-3 PUFA and (3) the possibility of a threshold for sufficient intake.

  • The cross-sectional ecological design of this study means that it cannot provide strong evidence for a causal association on the level of the individual, but this evidence already exists, and our study provides essential contextual information.

  • Increasing LC omega-3 PUFA intake norms may lower PTB rates in 157 of the 184 countries studied.


Preterm birth (PTB), or pregnancy lasting <37 weeks, is a common obstetrical problem associated with a number of immediate and lifelong health problems, including neonatal death, acute and chronic lung disease, brain injuries and neurodevelopmental problems.1 2 These outcomes have enormous economic and public health impacts,1–5 providing strong motivation to understand modifiable processes that mediate risk. Here, we aim to better illuminate an emerging nutritional factor, long-chain omega-3 polyunsaturated fatty acid (LC omega-3 PUFA), the role of which has been obscured by the heterogeneity of unmeasured baseline intakes. To achieve this aim, we use country-level PTB rates and dietary fat intake estimates to (1) characterise the potential worldwide impact of this dietary factor and (2) reassess conclusions drawn from the prior literature.

Thirty years ago, landmark epidemiological observations from the Faroe Islands indicated that high dietary intake of fish oils (oils that are rich in LC omega-3 PUFAs) associated with longer gestation and improved fetal growth.6 7 Since then, follow-up studies including epidemiological investigations, laboratory experiments and randomised controlled trials attempted to test these associations.8–28 Initially, this work failed to definitively validate the fish oil hypothesis. In retrospect, this uncertainty should not be surprising given the complexity of the pathophysiology and the prior analytic issues that are only evident in hindsight (online supplementary table S1 and S2). However, three decades later consensus is finally developing, sufficient omega 3 PUFA intake increases gestational length, prevents PTB and increases birth weight (perhaps by extending gestation).29–33 Even more importantly, having adequate maternal LC omega-3 PUFA stores appears to result in healthier offspring (eg, improved neurocognitive development, decreased likelihood of atopy/allergy,34–36 and perhaps, decreased risk of stillbirth, infant death and Neonatal Intensive Care Unit admission31).

Here, we present an ecological analysis of PTB rates and country-level omega-3 PUFA intakes in 184 countries to characterise their relationship globally. Our analyses corroborate an emerging consensus in the individual level studies, and can inform the design of future interventions, including nutritional recommendations, fortification strategies, food system changes and primary care practices. The results also indicate that omega-3 intake prior to intervention can affect trial success, and because consumption varies across countries, prevention strategies may need to be context dependent.


We obtained, from published data, country-level estimates of PTB rates1 and fatty acid intakes37 38 in 184 countries for the year 2010, with methods as described elsewhere.1 37 These 184 countries were selected because they had data on both exposure (omega-3 intakes) and outcome (PTB rates). Briefly, the PTB rate data were estimated from four primary sources: (1) reproductive health surveys, (2) national statistical offices and registries, (3) published papers identified in a systematic literature review and (4) unpublished data from the Child Health Epidemiology Reference Group.1 PTB was defined as delivery prior to 37 weeks of gestation, and the data exclusion criteria and handling protocols are outlined in Blencowe et al.1 The authors put extensive effort into vetting, integrating and standardising the heterogeneous source data,1 and here we summarise the key points as we understand them.

All primary data sources had a minimum of 50 births, and datasets were excluded if the possibility of bias from seasonal PTB rate changes could not be assessed (Blencowe et al, p2164).1 The authors utilised a twofold quality screen to exclude primary data sources that demonstrated evidence of ‘poor case ascertainment’; data sources were excluded if: (1) fewer than 2% of the reported PTBs occurred before 28 weeks of gestation or (2) the PTB rate was reported to be <3 in 100 live births. This yielded 738 data sources, 74% of which were from developed, Latin American or Caribbean countries (note: these designations are Millennium Development Goal regions). The data from these largely developed regions were generally more dense and of higher quality than that of other regions of the world. The authors then incorporated covariate data and made two types of regression-based prediction models to estimate PTB rates for each country. Model 1 was used for the data dense countries and model 2 was used for the others. The authors used forward stepwise selection procedure to identity variables with predictive value to maintain in the models and though the two models were roughly similar, the differences between the PTB rate prediction models were not surprising (eg, mean adult female BMI was included in model 1, while malaria endemicity and female literacy rate were included in model 2). The final PTB rate was estimated in one of three ways depending on the limitations of the source data: (1) for the 13 countries with good vital registration data that used the standard definition of PTB, Loess regression was performed on that data, (2) for the 65 countries in the developed/data-dense regions that fell short of this ideal, prediction model 1 was used to estimate the PTB rate and (3) for the 106 countries outside of the developed/data-dense regions prediction model 2 was used to estimate the PTB rate.

The fatty acid intake data were generated for the 2010 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study by the Nutrition and Chronic Diseases Expert Group (NutriCoDE).37 39 40 As with the PTB rate data, the dietary information sources were diverse and extensive efforts were made to aggregate and harmonise the data for cross-country comparisons. Micha et al37 provides an overview flowchart of the survey identification process, and Micha et al40 has a 2000 word summary of the protocols. In short, national survey data were identified via Medline searches (outlined in the supplement40), but because some countries lacked official surveys, additional information was obtained from large epidemiological study cohorts, the WHO Stepwise Approach To Surveillance database, the WHO Global Infobase and other household surveys.37 The identified survey data were presented in many distinct metrics, and the original authors recalculated their estimates in uniform dietary units to facilitate cross-country comparisons when needed.37 40

A total of 266 surveys were identified and included: 27% single response dietary recall data, 14% multiple-response dietary recall data, 31% Food Frequency Questionnaire Data and 29% household availability/budget data.37 To account for the uncertainties associated with heterogeneous information sources and missing data, the authors used a Bayesian hierarchical imputation model to yield the mean consumption estimates.37

Seafood-based omega-3 intake was assessed as total dietary eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) intake in mg/day (excluding supplements).40 Plant-based omega-3 intake was assessed as total dietary alpha-linolenic acid (ALA) intake in mg/day (excluding supplements).40 Country-level omega-3 intake norms were available for males and females of at least 20 years of age, and because our outcome was PTB rate, we utilised only values from females ≥20 years of age.

To create a composite exposure metric that reflects both dietary sources of omega-3, we used available in vivo conversion estimates41 42 to combine seafood-based LC omega-3 PUFA intake and plant-based omega-3 PUFA. Because adult females convert ~20% of their ALA intake into EPA,41 42 we created the total LC omega-3 PUFA metric as follows:

Embedded Image

This approach to exposure assessment allowed for the integration of these two distinct sources into one biologically interpretable metric that reflects the net availability of LC omega-3 PUFA.

We hypothesise that if maternal LC omega-3 PUFA body stores/blood levels are important for increasing birth weight and extending gestation, then countries where women have low omega-3 PUFA intake should have higher PTB rates. We also expect countries with high omega-3 PUFA intakes to have lower PTB rates.

Because an intake threshold may exist above which PTB rate is no longer affected,9 43 44 we assessed the linearity of the omega-3–PTB relationship with a penalised spline. In short, we created a model with PTB rate as the outcome and total omega-3 PUFA intake as a smoothed exposure variable (a penalised spline). The spline was selected using a generalised cross-validation (GCV) procedure from GAM in the mgcv package in R V.3.5.0. GCV is a standardised iterative process that selects a smooth non-linear function when there is sufficient evidence of non-linearity.45 46 If there is insufficient evidence of a deviation from linearity then GCV selects a linear model. This process identified a non-linear smooth function for the omega-3–PTB relationship, indicating the existence of an exposure threshold. Because the relationship appeared linear below and above this threshold, we constructed linear regression models to (1) characterise these two linear regions of the relationship and (2) identify the putative threshold.

We did not attempt to identify an omega-3 PUFA intake level that would be sufficient for a given individual, nor did we attempt to estimate individual risk of PTB associated with low omega-3 intake. These analyses simply evaluate if reductions in country-level omega-3 PUFA intake are associated with elevated PTB rates. As with many country-level analyses, we had limited covariate information, and this constrained our ability to assess for potential confounding. However, one key variable was available: country income level. Blencowe et al listed the WHO country-level income categories based on per capita Gross National Income (GNI—World Bank Atlas Method—a variable with four levels; higher rank corresponds to higher income).1 All 184 countries had available GNI data. This allowed us to build regression models that yielded crude and income-adjusted associations between omega-3 PUFA intake and PTB rate. Regression analyses and splines were conducted with R V.3.5.0 (, and other analyses were performed with SAS V.9.4.

Because the ALA to EPA/DHA conversion rate (20%41 42) has not been extensively characterised, and there is reason to believe that both genetic47 48 and nutritional factors,49 50 could modify this rate, we also evaluated seafood-based and plant-based omega-3 as two separate independent variables. Our main analysis assumed that the conversion rate is known and constant across countries. However, the alternative approach, treating the two types of consumption as independent, adds a new assumption that we also find problematic: the biological meaning of plant omega-3 intake is not altered by seafood omega-3 intake (and vice versa). Because we know that both intakes contribute to the unmeasured exposure of interest (total LC omega-3 levels), they are difficult to interpret in isolation. Another imperfect, but useful way, to handle the uncertainty of the conversion rate is to evaluate a range of rates in a sensitivity analysis. This approach still assumes a constant conversion rate across countries, but it considers a variety of potential mean rates. Both of these alternative analyses are presented in the supplement.

Finally, there was an a priori reason to look for an interaction between omega-6 and omega-3 PUFA intake. Unfortunately, the available omega-6 intake data were calculated as a ‘percent of total energy intake’, which makes it incompatible with the omega-3 data (mg/day) and biologically uninterpretable in this interaction context.

Patient and public involvement

This is a cross-sectional study of published country-level data. There was no involvement of patients or the public.


For the 184 countries with intake and PTB data for 2010, the mean PTB rate was 10.2 per 100 live births (SD: 3.0), and the mean LC omega-3 PUFA level was 310 mg/day (SD: 383 mg/day) (table 1 and online supplementary table S3). LC omega-3 PUFA intake was positively correlated with the country income variable (Spearman rank correlation=0.44, and this correlation was unchanged when an omega-3 outlier, the Maldives, was removed; online supplementary figure S1).

Table 1

Descriptive statistics for all countries and the subsets on either side of the 600 mg/day threshold

In the full dataset (n=184), the GCV process detected evidence of non-linearity in the omega-3–PTB relationship, and selected a spline rather than a linear term to model the relationship (figure 1A). After the omega-3 intake outlier (The Maldives) was excluded, a very similar spline was obtained (figure 1B). In both panels, a threshold between 500 and 700 mg/day of LC omega-3 PUFA was detected.

Figure 1

Penalised spline modelling the omega-3–PTB relationship. (A) Country-level omega-3 intake norms among females are on the x-axis and country-level preterm birth rates are on the y-axis. Each vertical dash below the spline on the x-axis represents a single country, allowing the figure to convey data density throughout the exposure distribution. The shape of the spline is most certain in the areas of greatest data density. (B) Same as panel A except the Maldives were excluded, and the threshold is unchanged. LC omega-3 PUFA, long-chain omega-3 polyunsaturated fatty acid; PTB, preterm birth.

The relationship appears linear below 600 mg/day, with PTB rates decreasing as LC omega-3 PUFA intake increases. Above 600 mg/day, there is no significant relationship between PTB rates and omega-3 PUFA intake. The results from unadjusted and income-adjusted linear regression models above and below this threshold are presented in table 2. The Maldives were excluded as an outlier in the data above the threshold (n=26), but the results were similar when this outlier was included (online supplementary table S4).

Table 2

Results from regression models within the two linear sections of the omega-3–PTB relationship

The unadjusted model for countries below 600 mg/day intake (n=157) indicates that the number of preterm births per 100 live births decreases by 2.9 (95% CI 4.2 to 1.6) for each 1 SD increase in omega-3 intake norms (383 mg/day). After adjustment for country income, the model indicates that the number of preterm births per 100 live births decreases by 1.5 (95% CI 2.8 to 0.3) for each 1 SD increase in daily omega-3 intake. Note that the splines presented in figure 1 do not specify an exact threshold value. Six hundred milligrams per day is a visual estimate but we also examined alternative thresholds to understand the effect of changing this value (online supplementary table S5). Increasing the threshold value above 600 mg/day increases power, as it increases the number of countries analysed, but it may violate assumption of linearity. The omega-3–PTB relationship below the threshold is significant in the unadjusted linear model regardless of the specified cut-off (400, 500, 600, 700, 800 or 900 mg/day). In the adjusted model, the relationship is significant only with thresholds of 600, 700 and 800 mg/day.

In the supplementary analysis which assessed seafood-based and plant-based omega-3 PUFA as separate independent variables, the penalised splines (online supplementary figure S2) again identified putative thresholds (600 mg/day in the seafood-based omega-3 analysis and 3000 mg/day in the plant-based omega-3 analysis). Additionally, the shape of the spline for the joint exposure metric was not altered by varying the ALA to EPA conversion rate assumption (online supplementary table S3), and the association with PTB rate (online supplementary table S6) was more significant when using the empirically determined conversion rate estimate (20%).41 42


We detected a threshold in the relationship between omega-3 PUFA intakes and country-level PTB rates; country-level PTB rates decreased with increasing LC omega-3 PUFA levels up to ~600 mg/day. Above 600 mg/day, omega-3 intake norms were not associated with country-level PTB rates. These conclusions remain after adjustment for country income. Because multiple causal structures51 can be drawn to represent the variables in this analysis (Figure S4), it is not clear if adjustment for county income reduces bias in this context, but the association is significant in both models, and confounding from country income cannot fully explain our findings. Furthermore, it is possible that elevated country income is a proxy for omega-3 supplement use, which is not included in our estimated consumption data. If this is the case, then adjusting for country income may underestimate the omega-3–PTB association, and our income-adjusted associations would be conservative.

We acknowledge that it is difficult to assess and account for potential confounding in an ecological study. Typically, very few relevant covariates will be available in a useful form, and our study was no exception. Variables that we might want to assess would be those which (1) associate with exposure (omega-3 intake), (2) independently associate with outcome (PTB rate) and (3) are not consequences of exposure (or mediating the effect of exposure on outcome).51 52 Any variables that we might suspect based on subject matter knowledge, and the rough criteria above, would need to be examined with directed acyclic graphs to determine if adjustment was likely to remove bias.51 52 Thus, nutrients and toxicants that are found in the same foods as omega-3 fatty acids could be of interest as potential confounders, if they are suspected to alter PTB risk. We would have assessed measures including, but not limited to, mean national: intakes of folic acid, iron and licorice,53 as well as circulating vitamin D levels,54 and chemical contaminants,55 but this information was not available.

Our results corroborate the emerging consensus of studies on the individual level: robust LC omega-3 PUFA intake is needed to maintain gestation, promote fetal growth and produce healthy offspring.29–31 34 35 56 Furthermore, our approach addresses a key weakness in the literature by accounting for intake of plant-based precursors in the estimation of LC omega-3 PUFA levels. Adult females convert ~20% of ingested plant-based omega-3 into LC omega-3 PUFA,41 42 but earlier studies in this area did not account for plant-based omega-3 intake. This underappreciated physiology may explain some of the heterogeneity in the literature. Additionally, our observation of an intake threshold on the country level is consistent with prior reports of an intake threshold on the individual level.9 43 44 LC omega-3 PUFA levels in prenatal maternal plasma are inversely related to the odds of early PTB (delivery at <34 weeks of gestation), but this relationship is only present when LC omega-3 PUFAs make up <2% of the total fatty acids in maternal plasma. These results in conjunction with ours provide convergent evidence for the existence of a biological threshold with important health implications.

Although country-level analyses have limitations with regard to causal inference on the level of the individual (ie, the ecological fallacy57 58), they can serve important public health functions57 and have a specific advantage in nutritional epidemiology.59 In particular, ecological studies are very useful when individual-level exposures, such as dietary factors, are hard to measure accurately due to extensive within-person variability.59 Overall, our country-level findings support the individual-level studies, laboratory experiments and randomised controlled trials in a distinct fashion, and this convergence allows for stronger conclusions.60 When considered along with the prior evidence,8–23 29–31 our results have implications for country-level prevention; omega-3 intake interventions cannot be well assessed in the absence of information on baseline dietary norms (see figure 2). Omega-3 interventions, on any level, may only be effective in the context of omega-3 insufficiency, and some of the heterogeneity in the prior literature may be due to unmeasured baseline intake.

Figure 2

Countries with high and low dietary intake norms for omega-3 PUFAs among females. Countries with >600 mg/day LC omega-3 PUFA intake are in green, the threshold from the spline. Countries with <217 mg/day LC omega-3 PUFA are in gold; these countries are at least 1 SD (383 mg/day) below the 600 mg/day threshold. Countries with intermediate intake levels (217–600 mg/day) are in white. Country names and intake levels are listed in online supplementary table S3. LC omega-3 PUFA, long-chain omega-3 polyunsaturated fatty acid.

Two meta-analyses have recently been published on the use of omega-3 supplementation for the prevention of PTB61 and recurrent PTB.62 Both reported trends indicating that omega-3 supplementation during pregnancy can prevent PTB, but the associations were not significant, and this was interpreted as a demonstration of inefficacy. However, when the characteristics of the nine papers included in these meta-analyses (seven for PTB9 63–68 and two for recurrent PTB12 21) are considered individually in the context of our current knowledge, we find that six studies are not amenable to clear interpretation, and three studies are supportive (see online supplementary table S1 and S2). Therefore, the inclusion of these six studies may have obscured a true association that our results support. Given the complexities of omega-3 biochemistry, perinatal physiology and the heterogeneity of baseline intakes, it is not surprising that limitations of these early trials have emerged as our knowledge has advanced. However, study designs are steadily improving, and more recent meta-analyses found significant effects of omega-3 in the prevention of PTB (<37 weeks) and early PTB (<34 weeks).32 69

We still have some important things to learn before we can intervene effectively. For example, EPA and DHA are typically measured together in one category, as was the case in our study, and this has generally precluded the assessment of potentially distinct associations between these subcategories of LC omega-3 PUFA. In fact, the most recent Cochrane review mentions this as a future research need.69 Additionally, excess LC omega-3 PUFA supplementation in pregnancy may carry its own risks (eg, possible increases in postterm deliveries, artificial inductions or caesarean sections67), and these potential risks would need to be characterised before initiating any widespread interventions. Would changes in dietary norms share the same theoretical risks as high-dose prenatal supplementation? This approach would be in line with recent calls to recognise the importance of preconception health in determining pregnancy outcomes.70–73 A comparable situation may be the example of folic acid fortification to reduce the incidence of neural tube defects.74 Intake recommendations were relatively ineffective, but fortification strategies yielded positive effects.75

Finally, we note that we have assessed one part of a complex adaptive system.76 Even as the role of omega-3 intake in PTB prevention is solidified, the development of interventions will require transdisciplinary evaluation77 and iterative trials to identify strategies that minimise unintended consequences. For example, how can we obtain these fatty acids in a sustainable fashion without increasing exposure to the toxicants or teratogens that may be found in fish?34 78–80 Narrow interventions may fail where holistic approaches are needed. Thus, important hurdles remain, but this line of inquiry presents a valuable opportunity to design effective nutritional interventions for preventing PTB.


Our results provide a distinct line of evidence supporting the conclusion that sufficient omega-3 intake can reduce the risk of PTB. Furthermore, these findings provide a rough estimate of the impact of low omega-3 PUFA intake on PTB rates worldwide. These findings, in isolation, do not provide compelling evidence for a causal association between omega-3 intake and PTB. However, these results taken with previous findings from a variety of approaches indicate this association not only exists but is causal.8–23 29–31 Therefore, we hypothesise that increasing omega-3 PUFA intake could decrease PTB rates in the 157 countries with estimated LC omega-3 PUFA levels less than 600 mg/day. Although more work remains to be done in identifying safe sustainable strategies for delivering omega-3 fatty acids, this evidence provides justification for exploring appropriate nutritional strategies to reduce PTB.


  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.
  33. 33.
  34. 34.
  35. 35.
  36. 36.
  37. 37.
  38. 38.
  39. 39.
  40. 40.
  41. 41.
  42. 42.
  43. 43.
  44. 44.
  45. 45.
  46. 46.
  47. 47.
  48. 48.
  49. 49.
  50. 50.
  51. 51.
  52. 52.
  53. 53.
  54. 54.
  55. 55.
  56. 56.
  57. 57.
  58. 58.
  59. 59.
  60. 60.
  61. 61.
  62. 62.
  63. 63.
  64. 64.
  65. 65.
  66. 66.
  67. 67.
  68. 68.
  69. 69.
  70. 70.
  71. 71.
  72. 72.
  73. 73.
  74. 74.
  75. 75.
  76. 76.
  77. 77.
  78. 78.
  79. 79.
  80. 80.
View Abstract


  • Contributors THC conceived of the primary study idea (based partly on prior work with SMW), conducted the analyses and drafted the manuscript. JB and SMW provided critical feedback and important analytic guidance, as well as key intellectual and writing contributions. SMW was the senior author and all authors approved the final version for submission.

  • Funding This work was supported in part by the March of Dimes Ohio Collaborative for the Prevention of Preterm Birth, and a National Institutes of Health grant P20 GM103534.

  • Disclaimer The funding sources had no involvement in the design or conduct of this research, the writing of the manuscript or the decision to submit it for publication. The depiction of boundaries on the map(s) in this article do not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. The map(s) are provided without any warranty of any kind, either express or implied.

  • Competing interests None declared.

  • Ethics approval This study combined and reanalysed two publically available datasets.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The study data are available in the supplement and additional data and details are available from the papers that we cited as data sources.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.